LY3493269 / Eli Lilly - LARVOL DELTA

A Multiple-Dose Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1 | N=42 | Terminated | Sponsor: Eli Lilly and Company | Completed ➔ Terminated; Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early.

Trial termination

A Multiple-Dose Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Eli Lilly and Company | Recruiting ➔ Completed | N=70 ➔ 42 | Trial completion date: Sep 2023 ➔ Jun 2023 | Trial primary completion date: Sep 2023 ➔ Jun 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date

A Multiple-Dose Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open

A Multiple-Dose Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial

A Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=56; Active, not recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Aug 2021 ➔ Nov 2021; Trial primary completion date: Aug 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date

A Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=56; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Enrollment closed

A Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=56; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of LY3493269 in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1; N=56; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Eli Lilly and Company; Trial completion date: May 2021 ➔ Aug 2021; Initiation date: Feb 2021 ➔ May 2021; Trial primary completion date: Apr 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date

A Safety Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Eli Lilly and Company; Recruiting ➔ Completed

Clinical • Trial completion

A Study of LY3493269 in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1; N=56; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P1 trial

A Safety Study of LY3493269 in Healthy Participants (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of LY3493269 in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1; N=56; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3493269 in Participants With Type 2 Diabetes (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus